MRC Centre for Drug Safety Science, Department of Pharmacology, University of Liverpool, Liverpool, United Kingdom.
J Allergy Clin Immunol. 2011 Jun;127(6):1543-51.e3. doi: 10.1016/j.jaci.2010.12.1119. Epub 2011 Feb 26.
Exposure of patients with cystic fibrosis to sulfonamides is associated with a high incidence of hypersensitivity reactions.
To compare mechanisms of antigen presentation and characterize the phenotype and function of T cells from sulfamethoxazole-hypersensitive patients with and without cystic fibrosis.
T cells were cloned from 6 patients and characterized in terms of phenotype and function. Antigen specificity and mechanisms of antigen presentation to specific clones were then explored. Antigen-presenting cell metabolism of sulfamethoxazole was quantified by ELISA. The involvement of metabolism in antigen presentation was evaluated by using enzyme inhibitors.
Enzyme inhibitable sulfamethoxazole-derived protein adducts were detected in antigen-presenting cells from patients with and without cystic fibrosis. A significantly higher quantity of adducts were detected with cells from patients with cystic fibrosis. Over 500 CD4(+) or CD8(+) T-cell clones were generated and shown to proliferate and kill target cells. Three patterns of MHC-restricted reactivity (sulfamethoxazole-responsive, sulfamethoxazole metabolite-responsive, and cross-reactive) were observed with clones from patients without cystic fibrosis. From patients with cystic fibrosis, sulfamethoxazole metabolite-responsive and cross-reactive, but not sulfamethoxazole-responsive, clones were observed. The response of the cross-reactive clones to sulfamethoxazole was dependent on adduct formation and was blocked by glutathione and enzyme inhibitors. Antigen-stimulated clones from patients with cystic fibrosis secreted higher levels of IFN-γ, IL-6, and IL-10, but lower levels of IL-17.
Sulfamethoxazole metabolism and protein adduct formation is critical for the stimulation of T cells from patients with cystic fibrosis. T cells from patients with cystic fibrosis secrete high levels of IFN-γ, IL-6, and IL-10.
囊性纤维化患者接触磺胺类药物会导致过敏反应发生率高。
比较抗原提呈的机制,并对磺胺甲恶唑过敏的囊性纤维化患者和非囊性纤维化患者的 T 细胞表型和功能进行特征描述。
从 6 名患者中克隆 T 细胞,并对其表型和功能进行鉴定。然后,探索针对特定克隆的抗原特异性和抗原提呈机制。通过 ELISA 定量测定磺胺甲恶唑的抗原呈递细胞代谢。通过使用酶抑制剂评估代谢在抗原提呈中的作用。
在有和没有囊性纤维化的患者的抗原呈递细胞中均检测到可酶抑制的磺胺甲恶唑衍生蛋白加合物。来自囊性纤维化患者的细胞中检测到的加合物数量明显更高。生成并显示出增殖和杀伤靶细胞能力的超过 500 个 CD4+或 CD8+T 细胞克隆。从没有囊性纤维化的患者中生成的克隆观察到 3 种 MHC 限制性反应模式(磺胺甲恶唑反应性、磺胺甲恶唑代谢物反应性和交叉反应性)。从囊性纤维化患者中观察到磺胺甲恶唑代谢物反应性和交叉反应性克隆,但没有磺胺甲恶唑反应性克隆。交叉反应性克隆对磺胺甲恶唑的反应取决于加合物的形成,并且可以被谷胱甘肽和酶抑制剂阻断。来自囊性纤维化患者的抗原刺激克隆分泌更高水平的 IFN-γ、IL-6 和 IL-10,但 IL-17 水平较低。
磺胺甲恶唑代谢和蛋白加合物形成对囊性纤维化患者 T 细胞的刺激至关重要。囊性纤维化患者的 T 细胞分泌高水平的 IFN-γ、IL-6 和 IL-10。